Skip to main content
50°
Mostly Cloudy
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
League of Women Voters SRI
League of Women Voters WS
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by SAB Biotherapeutics, Inc.
< Previous
1
2
Next >
SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update
November 06, 2024
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
SABS
SABSW
SAB BIO CEO to Participate in Fireside Chat at Guggenheim Securities Healthcare Innovation Conference
October 31, 2024
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
SABS
SABSW
SAB BIO CEO to Participate in Fireside Chat at 2024 Cantor Global Healthcare Conference
September 13, 2024
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
SABS
SABSW
SAB BIO Provides SAB-142 Clinical Trial Progress Update at the European Association for the Study of Diabetes Annual Meeting
September 09, 2024
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
SABS
SABSW
SAB BIO to Present at the European Association for the Study of Diabetes 60th Annual Meeting
September 04, 2024
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
SABS
SABSW
SAB BIO Announces Second Quarter 2024 Financial Results and Provides Company Updates
August 08, 2024
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
SABS
SABSW
SAB BIO Announces Founding of Clinical Advisory Board to Guide the Development of SAB-142 for Type 1 Diabetes
August 05, 2024
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
SABS
SABSW
SAB BIO Appoints Lucy To as Chief Financial Officer
July 31, 2024
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
SABS
SABSW
SAb Biotherapeutics Rebrands as SAB BIO
June 20, 2024
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
SABS
SABSW
SAB Biotherapeutics to Present at the American Diabetes Association 84th Scientific Sessions
June 18, 2024
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
SABS
SABSW
SAB Biotherapeutics Announces Departure of Chief Financial Officer
May 30, 2024
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
SABS
SABSW
FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics
May 21, 2024
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
SABS
SABSW
SAB Biotherapeutics Announces Q1 2024 Financial Results and Provides Company Updates
May 20, 2024
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
SABS
SABSW
SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of Directors
May 06, 2024
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
SABS
SABSW
SAB Biotherapeutics Provides SAB-142 Trial Update
April 16, 2024
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
SABS
SABSW
SAB Biotherapeutics to Present at INNODIA Annual Meeting
April 08, 2024
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
SABS
SABSW
SAB Biotherapeutics to Present at the Needham Virtual Healthcare Conference
April 04, 2024
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
SABS
SABSW
SAB Biotherapeutics Announces Clinical Partnership with Naval Medical Research Center to Advance Potential Influenza Treatment
March 25, 2024
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
SABS
SABSW
SAB Biotherapeutics to Present at the BIO CEO & Investor Conference
February 23, 2024
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
SABS
SABSW
SAB Biotherapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
February 08, 2024
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
SABS
SABSW
SAB Biotherapeutics Announces Executive Leadership Change
February 02, 2024
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
SABS
SABSW
SAB Biotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
January 23, 2024
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
SABS
SABSW
SAB Biotherapeutics Announces 1-for-10 Reverse Stock Split
January 02, 2024
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
SABS
SABSW
SAB Biotherapeutics Announces Commencement of the HUMAN Phase 1 Clinical Trial with SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes
November 29, 2023
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
SABS
SABSW
SAB Biotherapeutics Appoints Katie Ellias to the Board of Directors
November 20, 2023
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
SABS
SABSW
SAB Biotherapeutics Announces Completion of $67.1 Million Financing to Advance Potential Disease-Modifying Treatment for Type 1 Diabetes
November 14, 2023
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
SABS
SABSW
SAB Biotherapeutics Announces Q3 2023 Financial Results and Provides Company Updates
November 14, 2023
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
SABS
SABSW
SAB Biotherapeutics to Present at Piper Sandler Healthcare Conference
November 09, 2023
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
SABS
SABSW
SAB Biotherapeutics Appoints Michael G. King Jr. as Chief Financial Officer
October 24, 2023
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
SABS
SABSW
SAB Biotherapeutics Receives Australian Approval to Commence Phase 1 Clinical Trial of SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes
October 19, 2023
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
Tickers
SABS
SABSW
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.